The uncertainty surrounding the direction of Brexit has been a challenge in the life sciences and clinical supplies industry.

With a vast range of areas including IMP manufacturing, product QP release, market approval and shipping of materials being affected, it is important for sponsors running clinical studies in the UK, EU, both, or planning future studies in these regions, to have a robust plan in place to mitigate any potential Brexit challenges.

For Almac, providing continuity for sponsors and patients has been a priority as well as ensuring a guaranteed clinical supplies solution in preparation for the UK’s exit from the EU.

Download our case study to find out how Almac’s One Clinical Trial Supply Solution helped provided a sponsor with a seamless solution, guaranteeing uninterrupted service provision of clinical trial materials.